Navigation Links
IU Confidential Publishes Biotech Investment Report
Date:7/28/2011

NEW YORK, July 28, 2011 /PRNewswire/ -- Investor Uprising Confidential, the premium investment research service of Investor Uprising, has published its "Best of Biotech: Innovation in Life Sciences" report today. The 16-page report covers the hottest trends in biotech investing, tells investors how to get involved, and gives an overview of more than 16 companies including a model portfolio of 10 top stock picks.

(Logo: http://photos.prnewswire.com/prnh/20110728/NY41230LOGO)

Biotech stocks have been among the best performers of the last five years, according to Investor Uprising Confidential's research, and many of these gains are driven by scientific innovation in the biopharmaceuticals and diagnostics markets. This innovation cycle is likely to continue for some time, making biotech an attractive place to invest.

"Many investors remain unaware of the strength in biotech and are mystified about how to invest in the market," says Investor Uprising Confidential's Editor and Publisher, R. Scott Raynovich. "Consequently, they have missed out. We put together a report that covers all the trends and explains many different ways to get involved, including ETFs, mutual funds, and individual stocks."

The report includes summaries of 17 leading biotechnology companies, three mutual funds, and the leading biotech Exchange Traded Funds (ETFs). Among the companies included in the report are Amgen Inc. (Nasdaq: AMGN), Biogen Idec  (Nasdaq: BIIB), Celgene Inc. (Nasdaq: CELG), Gilead Sciences Inc. (Nasdaq: GILD), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Cubist Pharmaceuticals Inc. (Nasdaq: CBST), Dendreon Corp. (Nasdaq: DNDN), Illumina Inc. (Nasdaq: ILMN), and Seattle Genetics Inc. (Nasdaq: SGEN).

Investor Uprising Confidential produces premium in-depth reports aimed at informing the sophisticated investor about long-term trends in important growth markets. The Best of Biotech report is available as a single copy at $500, or as part of an Investor Uprising Confidential annual subscription. To look at the executive summary of the Biotech and the research service, go to http://www.investoruprising.com/confidential.

Sponsored by PR Newswire, Investor Uprising, as well as the recent launch of the "My News" feature on PRNewswire.com and monthly virtual Retail Investor Conferences (retailinvestorconferences.com), represents PR Newswire's strategy to facilitate engagement between the individual investor community and public companies.

About Investor Uprising

Investor Uprising is the individual investor's no-nonsense community for accessing business trends and investment strategies. Combining expert market commentary, fundamental analysis and on-the-ground reporting, Investor Uprising helps the reader find the best investment opportunities in global markets. Sponsored by PR Newswire and operated by UBM plc, Investor Uprising's community of contributors will reach millions of potential business readers around the world.

Media Contacts:
R. Scott Raynovich
Editor in Chief, Investor Uprising Confidential
(406) 582-5886 direct
(406) 599-7873 mobile
Scott.Raynovich@investoruprising.com

Noreen Seebacher
Community Editor, Investor Uprising
(201) 360-6773
Noreen.Seebacher@investoruprising.com


'/>"/>
SOURCE Investor Uprising
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
2. New Medical Supply Website Provides Confidentiality, Discounts for Consumers
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. GSK Publishes Payments for Research, Consulting and Advising by U.S. Healthcare Professionals
5. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
6. Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011
7. Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI
8. Cellectis Publishes Its Financial Statement for the First Half of 2010
9. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
10. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
11. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants totaling ... as part of its prestigious Bayer Hemophilia Awards Program (BHAP). ... Philadelphia and Uniformed Services University of ... among the winners. Grant recipients were announced last night during ... (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... of Echenberg Institute, is announcing a new safe and effective at-home VuVa ... other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, vulvar ... ... VuVa ... company, VuVatech LLC, fills a void in the women,s wellness market because ...
(Date:7/10/2017)... 2017 The Institute for In Vitro Sciences ... recipient of a VITROCELL® inhalation exposure system thanks to ... The device, which is designed to replace animals in ... cells to airborne test materials in an environment that ... system for testing combustible tobacco products, as well as ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 27, 2017 , ... GAFFEY Healthcare, a leading provider of ... to Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice ... executive officer (CEO). , Elrene has been with company since Oct 2014 and ...
(Date:7/27/2017)... , ... July 27, 2017 , ... Team Novo Nordisk, ... Brand to the men’s pro squad as a stagiaire for the remainder of the ... professional debut on July 31st at the Tour of Utah. , “Every season we ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. ... advancement in drug therapy for patients living with relapsing and primary multiple sclerosis ... B cell targeted therapy that has been proven to significantly reduce signs of ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we ... from San Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending ... orthodontic braces. In doing so, it offers an effective alternative to traditional braces. As ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... “We are ... offer the ability for patients to schedule an appointment online in real time,” said ... the Six Month Smiles provider directory will bring more Six Month Smiles patients to ...
Breaking Medicine News(10 mins):